Your browser doesn't support javascript.
loading
Association of dengue infection with anti-alpha-gal antibodies, IgM, IgG, IgG1, and IgG2.
Olajiga, Olayinka M; Maldonado-Ruiz, L Paulina; Fatehi, Soheila; Cardenas, Jenny C; Gonzalez, Maria U; Gutierrez-Silva, Lady Y; Londono-Renteria, Berlin; Park, Yoonseong.
Afiliación
  • Olajiga OM; Department of Entomology, Kansas State University, Manhattan, KS, United States.
  • Maldonado-Ruiz LP; Department of Entomology, Kansas State University, Manhattan, KS, United States.
  • Fatehi S; Department of Entomology, Kansas State University, Manhattan, KS, United States.
  • Cardenas JC; Laboratorio Clínico, Hospital Local Los Patios, Los Patios, Norte de Santander, Colombia.
  • Gonzalez MU; Laboratorio Clinico, Empresa Social Del Estado Hospital Emiro Quintero Cañizares, Ocaña, Norte de Santander, Colombia.
  • Gutierrez-Silva LY; Laboratorio Clínico, Hospital Erasmo Meoz, Cúcuta, Norte de Santander, Colombia.
  • Londono-Renteria B; Department of Entomology, Kansas State University, Manhattan, KS, United States.
  • Park Y; School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States.
Front Immunol ; 13: 1021016, 2022.
Article en En | MEDLINE | ID: mdl-36311743
Dengue virus (DENV) transmitted by the Aedes mosquitoes is the etiological agent of dengue fever, one of the fastest-growing reemerging mosquito-borne diseases on the planet with a 30-fold surge in the last five decades. Interestingly, many arthropod-borne pathogens, including DENV type 2, have been reported to contain an immunogenic glycan galactose-alpha1,3-galactose (alpha-Gal or aGal). The aGal molecule is a common oligosaccharide found in many microorganisms and in most mammals, except for humans and the Old-World primates. The loss of aGal in humans is considered to be an evolutionary innovation for enabling the production of specific antibodies against aGal that could be presented on the glycan of pathogens. The objective of this study was to evaluate different anti-aGal antibodies (IgM, IgG, IgG1, and IgG2) in people exposed to DENV. We observed a significant difference in anti-aGal IgG and IgG1 levels among dengue severity classifications. Furthermore, a significant positive correlation was observed between the anti-aGal IgG and the number of days with dengue symptoms in patients. Additionally, both anti-aGal IgM and IgG levels differ between the two geographical locations of patients. While the anti-aGal IgM and IgG2 levels were not significantly different according to the dengue severity levels, age was negatively correlated with anti-aGal IgM and positively correlated with anti-aGal IgG2. Significant involvement of aGal antibodies in Dengue infection processes is suggested based on the results. Our results open the need for further studies on the exact roles and the mechanisms of the aGal antibodies in Dengue infection.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dengue / Virus del Dengue Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dengue / Virus del Dengue Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza